A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults

NCT04271592 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: ABI-H3733 Liquid Oral Dosage Form
DRUG: ABI-H3733 Solid Oral Dosage Form
DRUG: Placebo to ABI-H3733 Liquid Oral Dosage Form
DRUG: Placebo to ABI-H3733 Solid Oral Dosage Form

Sponsor

Assembly Biosciences